(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of 3.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.
Enanta Pharmaceuticals's revenue in 2026 is $65,258,000.On average, 7 Wall Street analysts forecast ENTA's revenue for 2026 to be $2,044,282,841, with the lowest ENTA revenue forecast at $1,811,046,622, and the highest ENTA revenue forecast at $2,171,298,719. On average, 7 Wall Street analysts forecast ENTA's revenue for 2027 to be $1,954,722,230, with the lowest ENTA revenue forecast at $1,518,190,705, and the highest ENTA revenue forecast at $2,354,788,752.
In 2028, ENTA is forecast to generate $2,190,812,738 in revenue, with the lowest revenue forecast at $1,427,144,698 and the highest revenue forecast at $2,997,003,866.